SOHM, Inc. Announces Patent Allowance/Approval in South Korea
Rhea-AI Summary
SOHM Inc. (OTC PINK:SHMN) has received a Notice of Allowance/Approval from the South Korea Patent Office for its innovative ABBIE gene editing technology. The patent covers the utilization of CAS 9 RETROVIRAL INTEGRASE and CAS 9 RECOMBINASE SYSTEMS for targeted DNA incorporation into cells or organisms.
This milestone expands SOHM's intellectual property portfolio in a key market, supporting licensing opportunities for novel cell therapies, agriculture, and biofuel applications. The company aims to strengthen its position in the global gene editing and cell therapy market, currently valued at $7.96 billion and $4.74 billion respectively in 2023.
The technology is expected to advance the development of new cell therapies for cancer and congenital diseases, while also supporting biofuel development and crop engineering.
Positive
- Patent approval in South Korea expands intellectual property portfolio in a major market
- Technology enables multiple revenue streams through licensing in cell therapy, agriculture, and biofuel sectors
- Addresses large market opportunity: $7.96B gene editing and $4.74B cell therapy markets
Negative
- No immediate revenue impact mentioned from the patent approval
- Commercialization timeline and costs not specified
News Market Reaction 1 Alert
On the day this news was published, SHMN declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
CHINO HILLS, CA / ACCESS Newswire / April 16, 2025 / SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company specializing in generic drugs and gene-editing tools, a leader in Gene Editing and Cell Engineering is pleased to announce that it has received a Notice of Allowance/Approval from the South Korea Patent Office for its innovative technology entitled "CAS 9 RETROVIRAL INTEGRASE AND CAS 9 RECOMBINASE SYSTEMS FOR TARGETED INCORPORATION OF A DNA SEQUENCE INTO A GENOME OF A CELL OR ORGANISM." Korea Patent Application No. 10-27695915
This patent allowance is a significant milestone for SOHM Inc. as it expands its intellectual property portfolio in one of the largest and most dynamic markets in the world. The granted patent covers the utilization of our ABBIE gene editing technology for delivery of gene of interests into target cells or organisms. This supports licensing opportunities for the generation of novel cell therapies, and additional technologies in agriculture or biofuel, developed for commercialization. SOHM Inc's aim is to strengthen its competitive position in the global gene editing and cell therapy market valued at
"We are excited about the allowance of this patent in Korea, which underscores our commitment to innovation and our dedication to the future of targeted-integration technologies as the future of gene editing "said David Aguilar Ph.D. COO. "This development not only enhances our intellectual property strategy but also opens up new opportunities for collaboration and expansion within the Asian market."
The technology covered by the patent allowance is expected to facilitate the development of new cell therapies leading to possible cures for cancer and other congenital diseases. Technology will also lead to the development of safe sources of biofuel and support safe engineering of crops for human consumption.
For more information about SOHM Inc. and its groundbreaking work in biotechnology, please visit www.SOHM.com.
About SOHM, Inc.:
SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted gene editing solutions. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy. SOHM strives to transform the landscape of genome editing and improve the quality of life through scientific discovery.
For further information regarding this announcement or to explore potential collaborations, please contact:
SOHM, Inc.:
Name: Baron Night, CEO/Dr. David Aguilar, COO
Email: info@sohm.com
Phone: (714) 522-6700
Safe Harbor Statement:
This news release contains "forward-looking statements," which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.
SOURCE: SOHM, Inc
View the original press release on ACCESS Newswire
FAQ
What patent did SOHM (SHMN) receive in South Korea?
What is the market value of the gene editing industry SHMN is targeting?
What commercial applications does SHMN's new Korean patent cover?
How will SHMN's patented technology benefit medical research?
